Poseida Accounts Payable vs Total Liab Analysis

PSTX Stock

USD 9.31 0.02 0.21%

Poseida Therapeutics financial indicator trend analysis is much more than just breaking down Poseida Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Poseida Therapeutics is a good investment. Please check the relationship between Poseida Therapeutics Accounts Payable and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poseida Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Poseida Therapeutics Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Poseida Therapeutics' Accounts Payable and Total Liab is 0.53. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Poseida Therapeutics, assuming nothing else is changed. The correlation between historical values of Poseida Therapeutics' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Poseida Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Poseida Therapeutics' Accounts Payable and Total Liab go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Poseida Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Poseida Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Poseida Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Poseida Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poseida Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.At this time, Poseida Therapeutics' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 39.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 14.6 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	4.6M	5.2M	5.6M	3.4M
Total Operating Expenses	172.6K	190.4M	194.2M	203.9M

Reconciled Depreciation Total Operating Expenses

Poseida Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding
Other Current Liab		0.94	0.67	0.9	-0.91	0.27	0.22	0.74	0.94	0.72	0.84	0.63	0.75	0.82	0.71	0.78	0.77	0.31	0.42	0.78	0.02	0.79	0.73	-0.79	0.95	0.77
Total Current Liabilities	0.94		0.77	0.81	-0.98	0.46	0.09	0.8	0.91	0.77	0.88	0.71	0.8	0.9	0.62	0.82	0.79	0.19	0.56	0.81	0.04	0.89	0.78	-0.78	0.98	0.87
Other Liab	0.67	0.77		0.61	-0.84	0.43	0.44	0.61	0.7	0.89	0.88	0.68	0.88	0.9	0.58	0.82	0.94	0.0	0.56	0.83	0.51	0.92	0.88	-0.36	0.81	0.66
Net Tangible Assets	0.9	0.81	0.61		-0.83	0.2	0.45	0.61	0.97	0.83	0.84	0.72	0.85	0.83	0.94	0.88	0.69	0.13	0.5	0.88	0.0	0.72	0.84	-0.53	0.87	0.66
Retained Earnings	-0.91	-0.98	-0.84	-0.83		-0.52	-0.19	-0.75	-0.93	-0.85	-0.93	-0.8	-0.88	-0.95	-0.7	-0.89	-0.82	-0.07	-0.65	-0.89	-0.12	-0.93	-0.86	0.68	-0.99	-0.86
Accounts Payable	0.27	0.46	0.43	0.2	-0.52		-0.11	0.05	0.36	0.4	0.4	0.79	0.43	0.46	0.19	0.51	0.17	-0.7	0.88	0.51	0.25	0.4	0.41	-0.18	0.39	0.43
Other Assets	0.22	0.09	0.44	0.45	-0.19	-0.11		-0.17	0.3	0.57	0.28	0.3	0.55	0.31	0.58	0.48	0.46	-0.12	0.25	0.5	0.67	0.18	0.58	0.08	0.21	-0.18
Net Receivables	0.74	0.8	0.61	0.61	-0.75	0.05	-0.17		0.7	0.56	0.79	0.33	0.56	0.76	0.45	0.55	0.7	0.53	0.1	0.53	-0.3	0.84	0.54	-0.55	0.79	0.88
Other Stockholder Equity	0.94	0.91	0.7	0.97	-0.93	0.36	0.3	0.7		0.85	0.91	0.78	0.87	0.91	0.88	0.91	0.73	0.1	0.59	0.91	0.01	0.83	0.86	-0.6	0.95	0.79
Total Current Assets	0.72	0.77	0.89	0.83	-0.85	0.4	0.57	0.56	0.85		0.91	0.82	1.0	0.94	0.86	0.97	0.81	-0.13	0.69	0.98	0.34	0.87	1.0	-0.3	0.84	0.63
Common Stock	0.84	0.88	0.88	0.84	-0.93	0.4	0.28	0.79	0.91	0.91		0.79	0.91	0.99	0.8	0.93	0.86	0.06	0.57	0.92	0.1	0.96	0.9	-0.42	0.92	0.88
Property Plant Equipment	0.63	0.71	0.68	0.72	-0.8	0.79	0.3	0.33	0.78	0.82	0.79		0.83	0.82	0.75	0.91	0.52	-0.51	0.93	0.91	0.21	0.69	0.82	-0.25	0.72	0.65
Total Assets	0.75	0.8	0.88	0.85	-0.88	0.43	0.55	0.56	0.87	1.0	0.91	0.83		0.95	0.86	0.98	0.81	-0.12	0.71	0.98	0.34	0.87	1.0	-0.34	0.86	0.64
Short Long Term Debt Total	0.82	0.9	0.9	0.83	-0.95	0.46	0.31	0.76	0.91	0.94	0.99	0.82	0.95		0.79	0.95	0.85	0.0	0.64	0.94	0.16	0.97	0.94	-0.43	0.93	0.84
Total Stockholder Equity	0.71	0.62	0.58	0.94	-0.7	0.19	0.58	0.45	0.88	0.86	0.8	0.75	0.86	0.79		0.9	0.59	-0.08	0.56	0.9	0.07	0.64	0.85	-0.21	0.73	0.53
Property Plant And Equipment Net	0.78	0.82	0.82	0.88	-0.89	0.51	0.48	0.55	0.91	0.97	0.93	0.91	0.98	0.95	0.9		0.75	-0.2	0.77	1.0	0.24	0.85	0.97	-0.35	0.87	0.7
Current Deferred Revenue	0.77	0.79	0.94	0.69	-0.82	0.17	0.46	0.7	0.73	0.81	0.86	0.52	0.81	0.85	0.59	0.75		0.31	0.31	0.75	0.39	0.89	0.81	-0.5	0.83	0.67
Net Debt	0.31	0.19	0.0	0.13	-0.07	-0.7	-0.12	0.53	0.1	-0.13	0.06	-0.51	-0.12	0.0	-0.08	-0.2	0.31		-0.69	-0.2	-0.28	0.14	-0.12	-0.49	0.2	0.16
Cash	0.42	0.56	0.56	0.5	-0.65	0.88	0.25	0.1	0.59	0.69	0.57	0.93	0.71	0.64	0.56	0.77	0.31	-0.69		0.77	0.33	0.51	0.7	-0.16	0.55	0.42
Non Current Assets Total	0.78	0.81	0.83	0.88	-0.89	0.51	0.5	0.53	0.91	0.98	0.92	0.91	0.98	0.94	0.9	1.0	0.75	-0.2	0.77		0.27	0.84	0.98	-0.35	0.87	0.68
Non Currrent Assets Other	0.02	0.04	0.51	0.0	-0.12	0.25	0.67	-0.3	0.01	0.34	0.1	0.21	0.34	0.16	0.07	0.24	0.39	-0.28	0.33	0.27		0.15	0.36	0.04	0.09	-0.27
Long Term Debt	0.79	0.89	0.92	0.72	-0.93	0.4	0.18	0.84	0.83	0.87	0.96	0.69	0.87	0.97	0.64	0.85	0.89	0.14	0.51	0.84	0.15		0.86	-0.47	0.92	0.87
Cash And Short Term Investments	0.73	0.78	0.88	0.84	-0.86	0.41	0.58	0.54	0.86	1.0	0.9	0.82	1.0	0.94	0.85	0.97	0.81	-0.12	0.7	0.98	0.36	0.86		-0.33	0.85	0.62
Good Will	-0.79	-0.78	-0.36	-0.53	0.68	-0.18	0.08	-0.55	-0.6	-0.3	-0.42	-0.25	-0.34	-0.43	-0.21	-0.35	-0.5	-0.49	-0.16	-0.35	0.04	-0.47	-0.33		-0.72	-0.52
Common Stock Total Equity	0.95	0.98	0.81	0.87	-0.99	0.39	0.21	0.79	0.95	0.84	0.92	0.72	0.86	0.93	0.73	0.87	0.83	0.2	0.55	0.87	0.09	0.92	0.85	-0.72		0.84
Common Stock Shares Outstanding	0.77	0.87	0.66	0.66	-0.86	0.43	-0.18	0.88	0.79	0.63	0.88	0.65	0.64	0.84	0.53	0.7	0.67	0.16	0.42	0.68	-0.27	0.87	0.62	-0.52	0.84

Click cells to compare fundamentals

Poseida Therapeutics Account Relationship Matchups

Poseida Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	1.7M	19.6M	17.2M	20.2M	31.1M	32.6M
Total Current Liabilities	21.9M	30.0M	43.3M	53.9M	71.3M	74.9M
Other Liab	22.6M	25.0M	14.9M	27.5M	31.6M	16.9M
Net Tangible Assets	(155.1M)	256.4M	150.7M	182.0M	209.4M	219.8M
Retained Earnings	(152.2M)	(281.9M)	(406.9M)	(470.9M)	(594.3M)	(564.6M)
Accounts Payable	4.9M	763K	9.0M	2.2M	3.3M	3.5M
Other Assets	3.4M	28.6M	1.7M	1.1M	1.2M	1.2M
Other Stockholder Equity	(219.5M)	543.8M	563.1M	658.6M	697.9M	732.7M
Total Current Assets	127.2M	314.0M	213.9M	298.6M	226.5M	171.6M
Property Plant Equipment	10.9M	23.3M	48.2M	21.6M	24.8M	17.4M
Total Assets	147.0M	371.5M	269.3M	351.8M	273.9M	233.2M
Short Long Term Debt Total	29.1M	59.3M	61.2M	88.8M	85.4M	55.4M
Total Stockholder Equity	(149.5M)	262.0M	156.2M	187.6M	103.7M	70.7M
Property Plant And Equipment Net	10.9M	48.3M	48.2M	46.7M	40.8M	31.4M
Net Debt	(58.6M)	(24.7M)	(145.1M)	7.4M	41.0M	43.0M
Cash	87.8M	84.0M	206.3M	81.4M	44.5M	86.4M
Non Current Assets Total	19.8M	57.5M	55.4M	53.3M	47.4M	40.2M
Non Currrent Assets Other	3.4M	3.6M	1.7M	1.1M	1.1M	1.8M
Long Term Debt	26.1M	29.1M	29.4M	58.3M	58.6M	36.0M
Cash And Short Term Investments	125.3M	309.2M	206.3M	282.5M	212.2M	185.7M
Liabilities And Stockholders Equity	147.0M	371.5M	269.3M	351.8M	273.9M	233.2M
Non Current Liabilities Total	274.7M	79.5M	69.8M	110.4M	98.9M	90.7M
Other Current Assets	434K	4.8M	7.5M	7.0M	5.3M	4.0M
Total Liab	296.5M	109.5M	113.1M	164.2M	170.2M	162.5M
Net Invested Capital	(120.4M)	291.1M	185.6M	245.8M	162.3M	107.3M
Property Plant And Equipment Gross	10.9M	48.3M	57.4M	60.1M	59.6M	37.9M
Accumulated Other Comprehensive Income	19K	5K	0.0	(149K)	126K	132.3K
Non Current Liabilities Other	5.4M	50.3M	31.1M	30.7M	2.6M	2.5M
Net Working Capital	105.3M	284.0M	170.5M	244.7M	155.2M	155.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Poseida Accounts Payable vs Total Liab Analysis

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Liab

Poseida Therapeutics fundamental ratios Correlations

Poseida Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Poseida Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Poseida Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Short Long Term Debt Total	+ 0.99	Common Stock
Common Stock Total Equity	+ 0.98	Total Current Liabilities

Common Stock Total Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Short Long Term Debt Total	- 0.95	Retained Earnings
Long Term Debt	- 0.93	Retained Earnings
Common Stock	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.93	Retained Earnings